Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Cell Rep Med ; 1(7): 100101, 2020 10 20.
Artículo en Inglés | MEDLINE | ID: mdl-33103128

RESUMEN

Tumor-educated platelets (TEPs) are potential biomarkers for cancer diagnostics. We employ TEP-derived RNA panels, determined by swarm intelligence, to detect and monitor glioblastoma. We assessed specificity by comparing the spliced RNA profile of TEPs from glioblastoma patients with multiple sclerosis and brain metastasis patients (validation series, n = 157; accuracy, 80%; AUC, 0.81 [95% CI, 0.74-0.89; p < 0.001]). Second, analysis of patients with glioblastoma versus asymptomatic healthy controls in an independent validation series (n = 347) provided a detection accuracy of 95% and AUC of 0.97 (95% CI, 0.95-0.99; p < 0.001). Finally, we developed the digitalSWARM algorithm to improve monitoring of glioblastoma progression and demonstrate that the TEP tumor scores of individual glioblastoma patients represent tumor behavior and could be used to distinguish false positive progression from true progression (validation series, n = 20; accuracy, 85%; AUC, 0.86 [95% CI, 0.70-1.00; p < 0.012]). In conclusion, TEPs have potential as a minimally invasive biosource for blood-based diagnostics and monitoring of glioblastoma patients.


Asunto(s)
Plaquetas/metabolismo , Neoplasias Encefálicas/diagnóstico , Glioblastoma/diagnóstico , Monitoreo Fisiológico/métodos , Esclerosis Múltiple/diagnóstico , ARN Neoplásico/genética , Adulto , Anciano , Anciano de 80 o más Años , Algoritmos , Biomarcadores de Tumor/genética , Biomarcadores de Tumor/metabolismo , Plaquetas/patología , Neoplasias Encefálicas/genética , Neoplasias Encefálicas/mortalidad , Neoplasias Encefálicas/cirugía , Estudios de Casos y Controles , Progresión de la Enfermedad , Glioblastoma/genética , Glioblastoma/mortalidad , Glioblastoma/cirugía , Humanos , Persona de Mediana Edad , Esclerosis Múltiple/genética , Esclerosis Múltiple/patología , Metástasis de la Neoplasia , Empalme del ARN , ARN Neoplásico/metabolismo , Curva ROC , Análisis de Supervivencia , Microambiente Tumoral/genética
2.
Clin Cancer Res ; 24(6): 1337-1343, 2018 03 15.
Artículo en Inglés | MEDLINE | ID: mdl-29284707

RESUMEN

Purpose: We sought to investigate the clinical response to MET inhibition in patients diagnosed with structural MET alterations and to characterize their functional relevance in cellular models.Experimental Design: Patients were selected for treatment with crizotinib upon results of hybrid capture-based next-generation sequencing. To confirm the clinical observations, we analyzed cellular models that express these MET kinase alterations.Results: Three individual patients were identified to harbor alterations within the MET receptor. Two patients showed genomic rearrangements, leading to a gene fusion of KIF5B or STARD3NL and MET One patient diagnosed with an EML4-ALK rearrangement developed a MET kinase domain duplication as a resistance mechanism to ceritinib. All 3 patients showed a partial response to crizotinib that effectively inhibits MET and ALK among other kinases. The results were further confirmed using orthogonal cellular models.Conclusions: Crizotinib leads to a clinical response in patients with MET rearrangements. Our functional analyses together with the clinical data suggest that these structural alterations may represent actionable targets in lung cancer patients. Clin Cancer Res; 24(6); 1337-43. ©2017 AACR.


Asunto(s)
Adenocarcinoma del Pulmón/genética , Inhibidores de Proteínas Quinasas/farmacología , Proteínas Proto-Oncogénicas c-met/antagonistas & inhibidores , Proteínas Proto-Oncogénicas c-met/genética , Adenocarcinoma del Pulmón/diagnóstico , Adenocarcinoma del Pulmón/tratamiento farmacológico , Adenocarcinoma del Pulmón/metabolismo , Adulto , Quinasa de Linfoma Anaplásico/antagonistas & inhibidores , Crizotinib/farmacología , Crizotinib/uso terapéutico , Femenino , Duplicación de Gen , Reordenamiento Génico , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Terapia Molecular Dirigida , Estadificación de Neoplasias , Proteínas de Fusión Oncogénica/química , Proteínas de Fusión Oncogénica/genética , Proteínas de Fusión Oncogénica/metabolismo , Unión Proteica , Dominios y Motivos de Interacción de Proteínas , Inhibidores de Proteínas Quinasas/uso terapéutico , Proteínas Proto-Oncogénicas c-met/química , Tomografía Computarizada por Rayos X
3.
Oncotarget ; 8(36): 60447-60452, 2017 09 01.
Artículo en Inglés | MEDLINE | ID: mdl-28947983

RESUMEN

Historically, the diagnosis of diffuse intrinsic pontine glioma (DIPG) was based on typical imaging findings and clinical characteristics instead of pathology. However, the discovery of mutations in histone H3 variants, and the availability of tumor material for molecular analysis, has led to a paradigm shift in DIPG research and clinical practice. Using data from whole-brain autopsies in a series of nine DIPG patients with known histone mutational status, we here aim to review histopathological characteristics with special focus on intratumoral heterogeneity (ITH) and histone 3 K27 trimethylation (H3 K27me3). All DIPGs showed marked histologic ITH, with 56% even showing focal areas resembling a WHO grade I phenotype. As expected, H3 K27me3 immunoreactivity was lost in the tumors that were H3 K27M-mutated (seven patients; 67% H3.3, 11% H3.1). Strikingly, the H3K27 wildtype tumors (two patients; 22%) also contained H3 K27me3-immunonegative areas. Our study underscores the importance of the choice of the biopsy site, as ITH in DIPGs could theoretically lead to erroneous histological diagnoses with small biopsies. New in this respect is our finding that a substantial number of otherwise typical DIPGs has areas resembling WHO grade I tumors (esp. pilocytic astrocytoma, subependymoma). Furthermore, our study shows that negative H3 K27me3 immunohistochemistry in a DIPG does not imply a H3 K27-mutant tumor.

4.
Cancer Cell ; 32(2): 238-252.e9, 2017 08 14.
Artículo en Inglés | MEDLINE | ID: mdl-28810146

RESUMEN

Blood-based liquid biopsies, including tumor-educated blood platelets (TEPs), have emerged as promising biomarker sources for non-invasive detection of cancer. Here we demonstrate that particle-swarm optimization (PSO)-enhanced algorithms enable efficient selection of RNA biomarker panels from platelet RNA-sequencing libraries (n = 779). This resulted in accurate TEP-based detection of early- and late-stage non-small-cell lung cancer (n = 518 late-stage validation cohort, accuracy, 88%; AUC, 0.94; 95% CI, 0.92-0.96; p < 0.001; n = 106 early-stage validation cohort, accuracy, 81%; AUC, 0.89; 95% CI, 0.83-0.95; p < 0.001), independent of age of the individuals, smoking habits, whole-blood storage time, and various inflammatory conditions. PSO enabled selection of gene panels to diagnose cancer from TEPs, suggesting that swarm intelligence may also benefit the optimization of diagnostics readout of other liquid biopsy biosources.


Asunto(s)
Algoritmos , Inteligencia Artificial , Plaquetas/fisiología , Carcinoma de Pulmón de Células no Pequeñas/diagnóstico , Diagnóstico por Computador/métodos , Neoplasias Pulmonares/diagnóstico , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores de Tumor , Carcinoma de Pulmón de Células no Pequeñas/sangre , Carcinoma de Pulmón de Células no Pequeñas/genética , Estudios de Cohortes , Femenino , Perfilación de la Expresión Génica , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Inflamación/sangre , Inflamación/diagnóstico , Inflamación/genética , Neoplasias Pulmonares/sangre , Neoplasias Pulmonares/genética , Masculino , Persona de Mediana Edad , Máquina de Vectores de Soporte
5.
Oncotarget ; 7(1): 1066-75, 2016 Jan 05.
Artículo en Inglés | MEDLINE | ID: mdl-26544515

RESUMEN

PURPOSE: Non-small-cell lung cancers harboring EML4-ALK rearrangements are sensitive to crizotinib. However, despite initial response, most patients will eventually relapse, and monitoring EML4-ALK rearrangements over the course of treatment may help identify these patients. However, challenges associated with serial tumor biopsies have highlighted the need for blood-based assays for the monitoring of biomarkers. Platelets can sequester RNA released by tumor cells and are thus an attractive source for the non-invasive assessment of biomarkers. METHODS: EML4-ALK rearrangements were analyzed by RT-PCR in platelets and plasma isolated from blood obtained from 77 patients with non-small-cell lung cancer, 38 of whom had EML4-ALK-rearranged tumors. In a subset of 29 patients with EML4-ALK-rearranged tumors who were treated with crizotinib, EML4-ALK rearrangements in platelets were correlated with progression-free and overall survival. RESULTS: RT-PCR demonstrated 65% sensitivity and 100% specificity for the detection of EML4-ALK rearrangements in platelets. In the subset of 29 patients treated with crizotinib, progression-free survival was 3.7 months for patients with EML4-ALK+ platelets and 16 months for those with EML4-ALK- platelets (hazard ratio, 3.5; P = 0.02). Monitoring of EML4-ALK rearrangements in the platelets of one patient over a period of 30 months revealed crizotinib resistance two months prior to radiographic disease progression. CONCLUSIONS: Platelets are a valuable source for the non-invasive detection of EML4-ALK rearrangements and may prove useful for predicting and monitoring outcome to crizotinib, thereby improving clinical decisions based on radiographic imaging alone.


Asunto(s)
Plaquetas/metabolismo , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Neoplasias Pulmonares/tratamiento farmacológico , Proteínas de Fusión Oncogénica/genética , Pirazoles/uso terapéutico , Piridinas/uso terapéutico , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma de Pulmón de Células no Pequeñas/sangre , Carcinoma de Pulmón de Células no Pequeñas/genética , Crizotinib , Monitoreo de Drogas/métodos , Femenino , Humanos , Hibridación Fluorescente in Situ , Estimación de Kaplan-Meier , Neoplasias Pulmonares/sangre , Neoplasias Pulmonares/genética , Masculino , Persona de Mediana Edad , Proteínas de Fusión Oncogénica/sangre , Evaluación de Resultado en la Atención de Salud/métodos , Evaluación de Resultado en la Atención de Salud/estadística & datos numéricos , Pronóstico , Modelos de Riesgos Proporcionales , Inhibidores de Proteínas Quinasas/uso terapéutico , Reproducibilidad de los Resultados , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa
6.
Cancer Cell ; 28(5): 666-676, 2015 Nov 09.
Artículo en Inglés | MEDLINE | ID: mdl-26525104

RESUMEN

Tumor-educated blood platelets (TEPs) are implicated as central players in the systemic and local responses to tumor growth, thereby altering their RNA profile. We determined the diagnostic potential of TEPs by mRNA sequencing of 283 platelet samples. We distinguished 228 patients with localized and metastasized tumors from 55 healthy individuals with 96% accuracy. Across six different tumor types, the location of the primary tumor was correctly identified with 71% accuracy. Also, MET or HER2-positive, and mutant KRAS, EGFR, or PIK3CA tumors were accurately distinguished using surrogate TEP mRNA profiles. Our results indicate that blood platelets provide a valuable platform for pan-cancer, multiclass cancer, and companion diagnostics, possibly enabling clinical advances in blood-based "liquid biopsies".


Asunto(s)
Biomarcadores de Tumor/genética , Plaquetas/metabolismo , Neoplasias/genética , Transducción de Señal/genética , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores de Tumor/sangre , Fosfatidilinositol 3-Quinasa Clase I , Receptores ErbB/genética , Femenino , Perfilación de la Expresión Génica/métodos , Ontología de Genes , Humanos , Masculino , Persona de Mediana Edad , Mutación , Neoplasias/sangre , Neoplasias/diagnóstico , Patología Molecular/métodos , Fosfatidilinositol 3-Quinasas/genética , Proteínas Proto-Oncogénicas c-met/genética , Proteínas Proto-Oncogénicas p21(ras)/genética , Receptor ErbB-2/genética , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Análisis de Secuencia de ARN/métodos , Máquina de Vectores de Soporte , Adulto Joven
7.
J Neurosci Methods ; 238: 88-94, 2014 Dec 30.
Artículo en Inglés | MEDLINE | ID: mdl-25263805

RESUMEN

BACKGROUND: Systemic delivery of therapeutic agents remains ineffective against diffuse intrinsic pontine glioma (DIPG), possibly due to an intact blood-brain-barrier (BBB) and to dose-limiting toxicity of systemic chemotherapeutic agents. Convection-enhanced delivery (CED) into the brainstem may provide an effective local delivery alternative for DIPG patients. NEW METHOD: The aim of this study is to develop a method to perform CED into the murine brainstem and to test this method using the chemotherapeutic agent carmustine (BiCNU). To this end, a newly designed murine CED catheter was tested in vitro and in vivo. After determination of safety and distribution, mice bearing VUMC-DIPG-3 and E98FM-DIPG brainstem tumors were treated with carmustine dissolved in DW 5% or carmustine dissolved in 10% ethanol. RESULTS: Our results show that CED into the murine brainstem is feasible and well tolerated by mice with and without brainstem tumors. CED of carmustine dissolved in 5% DW increased median survival of mice with VUMC-DIPG-3 and E98FM-DIPG tumors with 35% and 25% respectively. Dissolving carmustine in 10% ethanol further improved survival to 45% in mice with E98FM-DIPG tumors. COMPARISON WITH EXISTING METHODS: Since genetically engineered and primary DIPG models are currently only available in mice, murine CED studies have clear advantages over CED studies in other animals. CONCLUSION: CED in the murine brainstem can be performed safely, is well tolerated and can be used to study efficacy of chemotherapeutic agents orthotopically. These results set the foundation for more CED studies in murine DIPG models.


Asunto(s)
Antineoplásicos/administración & dosificación , Tronco Encefálico/efectos de los fármacos , Carmustina/administración & dosificación , Catéteres , Convección , Sistemas de Liberación de Medicamentos/métodos , Animales , Tronco Encefálico/patología , Neoplasias del Tronco Encefálico/tratamiento farmacológico , Neoplasias del Tronco Encefálico/patología , Neoplasias del Tronco Encefálico/fisiopatología , Diseño de Equipo , Etanol/química , Estudios de Factibilidad , Glioma/tratamiento farmacológico , Glioma/patología , Glioma/fisiopatología , Glucosa/química , Humanos , Estimación de Kaplan-Meier , Ratones Endogámicos BALB C , Ratones Desnudos , Ratones Transgénicos , Trasplante de Neoplasias , Solventes/química , Resultado del Tratamiento
9.
Acta Neuropathol ; 127(6): 897-909, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24777482

RESUMEN

Diffuse intrinsic pontine glioma (DIPG), with a median survival of only 9 months, is the leading cause of pediatric brain cancer mortality. Dearth of tumor tissue for research has limited progress in this disease until recently. New experimental models for DIPG research are now emerging. To develop preclinical models of DIPG, two different methods were adopted: cells obtained at autopsy (1) were directly xenografted orthotopically into the pons of immunodeficient mice without an intervening cell culture step or (2) were first cultured in vitro and, upon successful expansion, injected in vivo. Both strategies resulted in pontine tumors histopathologically similar to the original human DIPG tumors. However, following the direct transplantation method all tumors proved to be composed of murine and not of human cells. This is in contrast to the indirect method that included initial in vitro culture and resulted in xenografts comprising human cells. Of note, direct injection of cells obtained postmortem from the pons and frontal lobe of human brains not affected by cancer did not give rise to neoplasms. The murine pontine tumors exhibited an immunophenotype similar to human DIPG, but were also positive for microglia/macrophage markers, such as CD45, CD68 and CD11b. Serial orthotopic injection of these murine cells results in lethal tumors in recipient mice. Direct injection of human DIPG cells in vivo can give rise to malignant murine tumors. This represents an important caveat for xenotransplantation models of DIPG. In contrast, an initial in vitro culture step can allow establishment of human orthotopic xenografts. The mechanism underlying this phenomenon observed with direct xenotransplantation remains an open question.


Asunto(s)
Neoplasias del Tronco Encefálico , Modelos Animales de Enfermedad , Glioma , Trasplante de Neoplasias/métodos , Animales , Antígenos CD/metabolismo , Antígenos de Diferenciación Mielomonocítica/metabolismo , Neoplasias del Tronco Encefálico/genética , Neoplasias del Tronco Encefálico/patología , Neoplasias del Tronco Encefálico/fisiopatología , Antígeno CD11b/metabolismo , Técnicas de Cultivo de Célula , Niño , Femenino , Lóbulo Frontal/patología , Lóbulo Frontal/fisiopatología , Lóbulo Frontal/trasplante , Glioma/genética , Glioma/patología , Glioma/fisiopatología , Humanos , Lactante , Antígenos Comunes de Leucocito/metabolismo , Masculino , Ratones Desnudos , Ratones SCID , Ratones Transgénicos , Puente/patología , Puente/fisiopatología , Puente/trasplante , Adulto Joven
10.
Mol Cancer Ther ; 12(2): 141-50, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23270927

RESUMEN

Diffuse intrinsic pontine glioma (DIPG) is a fatal pediatric disease. Thus far, no therapeutic agent has proven beneficial in the treatment of this malignancy. Therefore, conventional DNA-damaging radiotherapy remains the standard treatment, providing transient neurologic improvement without improving the probability of overall survival. During radiotherapy, WEE1 kinase controls the G(2) cell-cycle checkpoint, allowing for repair of irradiation (IR)-induced DNA damage. Here, we show that WEE1 kinase is one of the highest overexpressed kinases in primary DIPG tissues compared with matching non-neoplastic brain tissues. Inhibition of WEE1 by MK-1775 treatment of DIPG cells inhibited the IR-induced WEE1-mediated phosphorylation of CDC2, resulting in reduced G(2)-M arrest and decreased cell viability. Finally, we show that MK-1775 enhances the radiation response of E98-Fluc-mCherry DIPG mouse xenografts. Altogether, these results show that inhibition of WEE1 kinase in conjunction with radiotherapy holds potential as a therapeutic approach for the treatment of DIPG.


Asunto(s)
Neoplasias del Tronco Encefálico/tratamiento farmacológico , Neoplasias del Tronco Encefálico/radioterapia , Proteínas de Ciclo Celular/antagonistas & inhibidores , Glioma/tratamiento farmacológico , Glioma/radioterapia , Proteínas Nucleares/antagonistas & inhibidores , Proteínas Tirosina Quinasas/antagonistas & inhibidores , Animales , Neoplasias del Tronco Encefálico/enzimología , Neoplasias del Tronco Encefálico/patología , Terapia Combinada , Femenino , Glioma/enzimología , Glioma/patología , Humanos , Inmunohistoquímica , Ratones , Ratones Desnudos , Fosforilación , Pirazoles/farmacología , Pirimidinas/farmacología , Pirimidinonas , Fármacos Sensibilizantes a Radiaciones/farmacología , Distribución Aleatoria , Ensayos Antitumor por Modelo de Xenoinjerto
11.
J Virol ; 82(20): 10312-7, 2008 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-18667517

RESUMEN

Coronaviruses are positive-strand RNA viruses of extraordinary genetic complexity and diversity. In addition to a common set of genes for replicase and structural proteins, each coronavirus may carry multiple group-specific genes apparently acquired through relatively recent heterologous recombination events. Here we describe an accessory gene, ORF3, unique to canine coronavirus type I (CCoV-I) and characterize its product, glycoprotein gp3. Whereas ORF3 is conserved in CCoV-I, only remnants remain in CCoV-II and CCoV-II-derived porcine and feline coronaviruses. Our findings provide insight into the evolutionary history of coronavirus group 1a and into the dynamics of gain and loss of accessory genes.


Asunto(s)
Coronavirus Canino/genética , Coronavirus Canino/metabolismo , Glicoproteínas/metabolismo , Proteínas del Envoltorio Viral/metabolismo , Secuencia de Aminoácidos , Animales , Gatos , Análisis por Conglomerados , Infecciones por Coronavirus/metabolismo , Coronavirus Canino/clasificación , Perros , Glicoproteínas/genética , Datos de Secuencia Molecular , Sistemas de Lectura Abierta , Filogenia , Porcinos , Proteínas del Envoltorio Viral/genética
12.
Microb Drug Resist ; 11(4): 383-6, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-16359199
13.
J Virol ; 79(22): 14122-30, 2005 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-16254347

RESUMEN

In feline coronavirus (FCoV) pathogenesis, the ability to infect macrophages is an essential virulence factor. Whereas the low-virulence feline enteric coronavirus (FECV) isolates primarily replicate in the epithelial cells of the enteric tract, highly virulent feline infectious peritonitis virus (FIPV) isolates have acquired the ability to replicate efficiently in macrophages, which allows rapid dissemination of the virulent virus throughout the body. FIPV 79-1146 and FECV 79-1683 are two genetically closely related representatives of the two pathotypes. Whereas FECV 79-1683 causes at the most a mild enteritis in young kittens, FIPV 79-1146 almost invariably induces a lethal peritonitis. The virulence phenotypes correlate with the abilities of these viruses to infect and replicate in macrophages, a feature of FIPV 79-1146 but not of FECV 79-1683. To identify the genetic determinants of the FIPV 79-1146 macrophage tropism, we exchanged regions of its genome with the corresponding parts of FECV 79-1683, after which the ability of the FIPV/FECV hybrid viruses to infect macrophages was tested. Thus, we established that the FIPV spike protein is the determinant for efficient macrophage infection. Interestingly, this property mapped to the C-terminal domain of the protein, implying that the difference in infection efficiency between the two viruses is not determined at the level of receptor usage, which we confirmed by showing that infection by both viruses was equally blocked by antibodies directed against the feline aminopeptidase N receptor. The implications of these findings are discussed.


Asunto(s)
Coronavirus Felino/genética , Coronavirus Felino/patogenicidad , Panleucopenia Felina/patología , Macrófagos/fisiología , Macrófagos/virología , Glicoproteínas de Membrana/genética , Proteínas del Envoltorio Viral/genética , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Células de la Médula Ósea/patología , Células de la Médula Ósea/virología , Gatos , Técnicas de Cultivo de Célula , Secuencia Conservada , Coronavirus Felino/fisiología , Cartilla de ADN , Glicoproteínas de Membrana/química , Datos de Secuencia Molecular , Mutación , Plásmidos , ARN Viral/genética , Alineación de Secuencia , Homología de Secuencia de Aminoácido , Glicoproteína de la Espiga del Coronavirus , Proteínas del Envoltorio Viral/química , Replicación Viral
14.
Microb Drug Resist ; 11(1): 53-7, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-15770095

RESUMEN

The presence and character of class 1 integrons in multidrug-resistant Escherichia coli from slaughter animals and meat was determined by integrase-specific PCR and conserved segment PCR-restriction fragment length polymorphism (RFLP). At least five different class 1 integron types were found and three types were shared between hospitalized patients, humans in the community, meat, and slaughter animals. Common integron types indicate that antibiotic resistance genes are exchanged via the food chain between different reservoirs of both human and animal origin.


Asunto(s)
Resistencia a Múltiples Medicamentos , Escherichia coli/genética , Microbiología de Alimentos , Integrones/genética , Animales , Bovinos , Escherichia coli/enzimología , Escherichia coli/aislamiento & purificación , Infecciones por Escherichia coli/microbiología , Infecciones por Escherichia coli/veterinaria , Integrasas/genética , Países Bajos , Reacción en Cadena de la Polimerasa , Polimorfismo de Longitud del Fragmento de Restricción
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...